We offer double-stranded RNA developed based on the results obtained from collaborative research!
We offer double-stranded RNA "miRNA mimic" with chemical modifications on the passenger strand and double-stranded RNA "S-TuD" primarily composed of 2’-O-Methyl RNA. The "miRNA mimic" allows you to observe the activity of the mature miRNA itself by inactivating the passenger strand. The "S-TuD" specifically binds to the Micro RNA Binding Site (MBS) of the RISC complexed mature miRNA and strongly inhibits miRNA activity even at low concentrations. 【Features】 ■ miRNA mimic - Double-stranded RNA with chemical modifications on the passenger strand - Enables observation of the activity of the mature miRNA itself - Product developed based on results obtained from collaborative research ■ S-TuD - Double-stranded RNA primarily composed of 2’-O-Methyl RNA - Strongly inhibits miRNA activity even at low concentrations - Negative control sequences are also available *For more details, please refer to the external link page or feel free to contact us.
Inquire About This Product
basic information
For more details, please refer to the external link page or feel free to contact us.
Price range
P2
Delivery Time
P4
※*It may vary depending on the production volume. Please feel free to contact us.
Applications/Examples of results
For more details, please refer to the external link page or feel free to contact us.
Company information
Ajinomoto Bio-Pharma Services and GeneDesign, Inc. are engaged in the production of oligonucleotides, incorporating the latest technologies and patent licenses from various research institutions. We supply distinctive nucleic acid materials, including the introduction of artificially modified nucleic acids and the addition of functional molecules, contributing to the development of new technologies in the gene-related fields (such as drug development, diagnostic technology development, and bio-research technology development). Currently, the demand for various synthetic nucleic acids is expanding from cell culture levels to animal testing and further to clinical trials. Our company has established a system capable of supplying everything from research reagents to investigational drugs at all scales, and we are advancing research and development daily as a company that can significantly contribute to the creation of nucleic acid pharmaceuticals and the practical application of diagnostic systems. For the future of medicine, we aim to be a company that contributes to the welfare and health of people through the development of nucleic acid manufacturing technologies, actively working on the development of next-generation nucleic acid drugs and diagnostic materials.
